Tanja de Gruijl heads the Immunotherapy and Immune monitoring Lab at the Cancer Center of the VU University medical center (VUmc) in Amsterdam, where she has been appointed Professor of Translational Tumour Immunology and holds a Fenna Diemer Lindeboom Chair. She has over 25 years of experience in the field of tumour immunology and more than 190 publications to her name. Her research ranges from preclinical topics to immune monitoring of Phase I-III clinical trials. Her main line of research is the in vivo targeting and modulation of dendritic cells (DC) through genetic targeting and local cytokine or TLR-L administration. Further topics of research include tumour-mediated immune suppression, control of myeloid differentiation, the effects of cytostatic drugs on DC development and functionality, nanobody-mediated targeting of (NK)T-cell subsets, and the immune potentiation of tumour-draining lymph nodes and the tumour microenvironment. Her research has been supported by fellowships and grants from the Netherlands Organization for Scientific Research (NWO) and the Royal Dutch Cancer Society (KWF) and she is a recipient of a competitive research award of the Prostate Cancer Foundation. She has managed and supervised the research that has led to the allogeneic DC vaccination platform of the VUmc spin-off company DCPrime BV. She serves as scientific advisor to several biopharmaceutical companies and is co-founder of LAVA Therapeutics. She serves as an associate editor for Cancer Immunology Research and Clinical and Experimental Immunology. She is a member of the Grant Review committee of the Melanoma Research Alliance, a member of the scientific council of the Dutch Cancer Society, has chaired the Dutch Tumour Immunology Working Party, and is currently co-chair of the International Advisory Committee of the Society for the Immunotherapy of Cancer (SITC).